A Multicenter Phase II Clinical Study of Neoadjuvant Use of Camrelizumab in Combination With Chemotherapy for Organ Preservation in Esophageal Cancer

Clinical trial NCT06869226 · RECRUITING

Trial details

NCT number: NCT06869226
Sponsor: Peking University Cancer Hospital & Institute
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Esophageal Cancer

Start date: 2025-04-30
Primary completion: 2029-12-31
Enrollment: 283

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.